Unpicking the risk/reward in healthcare stocks

2016 saw several blow-ups for large drug companies

clock • 2 min read

In a world where there continues to be much economic uncertainty, healthcare looks an increasingly attractive area for investors. Demographic changes such as an ageing population and increasing wealth underpin visible demand growth, writes Paul Major, co-manager of the BB Healthcare Trust.

The most popular way for UK investors to gain healthcare exposure has been through holdings in large pharmaceuticals companies, which are perceived as diversified and low risk. However, the reality can be very different. The issue is that, while you may think you are gaining exposure to a broad range of healthcare revenue streams, these companies are often reliant on the success of one or two drugs trials that account for the majority of future revenue and profit growth. Unpicking the risk/reward profile of these companies can be particularly hard for non-specialists to unravel. BB...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot